Janssen Pharmaceutica NV (20240325369). TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH NIRAPARIB simplified abstract

TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH NIRAPARIB

Organization Name

Janssen Pharmaceutica NV

Inventor(s)

Peter Francis of Raritan NJ (US)

Angela Mennicke Lopez-gitlitz of Los Angeles CA (US)

Natalie A Nutnick of Norristown PA (US)

Gary Edward Mason of New Hope PA (US)

Xin Zhao of Foster City CA (US)

Michael P Gormley of Mount Laurel NJ (US)

Yuangen Zhu of Towaco NJ (US)

Karen Ann Urtishak of Media PA (US)

Shibu Thomas of Lower Gwynedd PA (US)

Adam A Del Corral of River Edge NJ (US)

TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH NIRAPARIB - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240325369 titled 'TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH NIRAPARIB

The present invention involves a method to enhance the effectiveness of treating metastatic castration-resistant prostate cancer with biallelic DNA-repair anomalies in male humans who have undergone specific prior treatments.

• The method includes administering a once-daily oral dose of 300 mg niraparib to the male human patients.
• The biallelic DNA-repair anomalies can be BRCA (BRCA1, BRCA2, or a combination), non-BRCA (ATM, FANCA, PALB2, CHEK2, BRIP1, HDAC2, or any combination), or a mix of both.
• The male patients must have received taxane-based chemotherapy and androgen receptor-targeted therapy before starting this treatment.
• This method aims to improve the efficacy of treatment for this specific type of prostate cancer by targeting DNA-repair anomalies with niraparib.

Potential Applications: - Treatment of metastatic castration-resistant prostate cancer with biallelic DNA-repair anomalies. - Precision medicine approach for male patients with specific genetic mutations. - Advancement in personalized cancer therapy.

Problems Solved: - Addressing the challenges of treating metastatic castration-resistant prostate cancer with DNA-repair anomalies. - Enhancing the effectiveness of existing treatments for this type of cancer. - Tailoring treatment based on individual genetic characteristics.

Benefits: - Improved treatment outcomes for male patients with metastatic castration-resistant prostate cancer. - Targeted therapy based on genetic mutations. - Potential for better disease management and quality of life for patients.

Commercial Applications: Title: Enhanced Treatment Method for Metastatic Castration-Resistant Prostate Cancer Description: This technology offers a targeted approach to treating a specific subtype of prostate cancer, potentially leading to better patient outcomes and market opportunities in precision oncology.

Questions about the technology: 1. How does the once-daily oral dosing of niraparib improve the treatment efficacy for metastatic castration-resistant prostate cancer with DNA-repair anomalies? 2. What are the implications of targeting specific genetic mutations in male patients with this type of cancer?

Original Abstract Submitted

the present invention relates to a method of improving the efficacy of treatment of line 2+ metastatic castration-resistant prostate cancer (mcrpc) with biallelic dna-repair anomalies in a male human, wherein said biallelic dna-repair anomalies are selected from: i) brca (brca1, brca2, or a combination thereof), ii) non-brca (atm, fanca, palb2, chek2, brip1, hdac2, or any combination thereof): or iii) any combination thereof; wherein the male human has received prior taxane-based chemotherapy and androgen receptor (ar)-targeted therapy; said method of improving the efficacy of treatment comprising administering to said male human a once-daily oral dosing of 300 mg niraparib.